Adjuvant immunotherapy for high-risk renal cell carcinoma-now or never?
BJU Int
.
2024 Nov 8.
doi: 10.1111/bju.16584.
Online ahead of print.
Authors
Tivya Kulasegaran
1
2
,
Niara Oliveira
1
2
,
Craig Gedye
3
,
Shomik Sengupta
4
5
Affiliations
1
Mater Hospital Brisbane, Mater Misericordiae Ltd., South Brisbane, Queensland, Australia.
2
School of Clinical Medicine, Mater Clinical Unit, The University of Queensland, Brisbane, Queensland, Australia.
3
Icon Cancer Centre Adelaide, Kurralta Park, South Australia, Australia.
4
Department of Urology, Eastern Health, Box Hill, Victoria, Australia.
5
Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia.
PMID:
39513301
DOI:
10.1111/bju.16584
No abstract available